Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia lifts ban on trials involving xenotransplantation

This article was originally published in RAJ Devices

Executive Summary

Australia’s National Health and Medical Research Council has ended the country’s ban on clinical trials involving xenotransplantation1-3. Such trials will be allowed to proceed once stringent regulatory and surveillance frameworks are put in place. The moratorium on trials involving animal-to-human transplantation has been in place since 2004.

You may also be interested in...



Next To No Uptake On UK Patient Preference Study Advice

More than a year after UK health technology assessment body NICE started offering scientific advice on designing patient preference studies, only two companies have sought guidance. NICE has also contributed to related projects that it hopes will increase the relevance of such studies in the context of an HTA appraisal.

EU Framework For Patient Preference Studies Under Review

An EU public-private collaborative project is seeking validation from regulators and health technology assessment bodies regarding its proposed best practice approach to conducting patient preference studies.

EU Framework For Patient Preference Studies Under Review

An EU public-private collaborative project is seeking validation from regulators and health technology assessment bodies regarding its proposed best practice approach to conducting patient preference studies.

UsernamePublicRestriction

Register

LL1134446

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel